Scott Boilen Net Worth

Scott Boilen biography

Scott Boilen serves as Independent Director of the Company. Mr. Boilen has served as the Chief Executive Officer of Allstar Products Group since 1999. He also served on the Board of Directors for the Electronic Retailing Association from 2010 to 2012 and the Board of Directors for the Food Bank for Westchester (New York) since 2009. Mr. Boilen holds a degree in Business Administration from the State University of New York at Albany and a Master’s Degree in Business Administration from Fordham University. Based on Mr. Boilen’s extensive management experience and in-depth understanding of the Company’s business, the Board of Directors believes that Mr. Boilen has the appropriate set of skills to serve as a member of the Board in light of the Company’s business and structure.

What is the salary of Scott Boilen?

As the Independent Director of Checkpoint Therapeutics Inc, the total compensation of Scott Boilen at Checkpoint Therapeutics Inc is $100,002. There are 6 executives at Checkpoint Therapeutics Inc getting paid more, with James Oliviero having the highest compensation of $2,308,250.

How old is Scott Boilen?

Scott Boilen is 53, he's been the Independent Director of Checkpoint Therapeutics Inc since 2016. There are 5 older and 4 younger executives at Checkpoint Therapeutics Inc. The oldest executive at Checkpoint Therapeutics Inc is Lindsay Rosenwald, 65, who is the Director.

What's Scott Boilen's mailing address?

Scott's mailing address filed with the SEC is 95 SAWYER ROAD, SUITE 110, , WALTHAM, MA, 02453.

Insiders trading at Checkpoint Therapeutics Inc

Over the last 8 years, insiders at Checkpoint Therapeutics Inc have traded over $1,535,168 worth of Checkpoint Therapeutics Inc stock and bought 200,000 units worth $356,000 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss oraz James F Iii Oliviero. On average, Checkpoint Therapeutics Inc executives and independent directors trade stock every 94 days with the average trade being worth of $93,898. The most recent stock trade was executed by James F Iii Oliviero on 26 June 2024, trading 24,610 units of CKPT stock currently worth $50,451.

What does Checkpoint Therapeutics Inc do?

checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr

Checkpoint Therapeutics Inc executives and stock owners

Checkpoint Therapeutics Inc executives and other stock owners filed with the SEC include:

• James Oliviero,
  President, Chief Executive Officer, Director
• James F. Oliviero III, C.F.A., CFA,
  Pres, CEO & Director
• William Gray,
  Vice President - Finance and Accounting, Principal Financial Officer, Corporate Secretary
• William Garrett Gray,
  CFO, Corp. Sec. & Treasurer
• Neil Herskowitz,
  Independent Director
• Michael Weiss,
  Chairman of the Board
• Barry Salzman,
  Independent Director
• Scott Boilen,
  Independent Director
• Christian Bechon,
  Independent Director
• Lindsay Rosenwald,
  Director
• Biotech, Inc. Fortress,
  10% owner
• Sharma Amit,
  Director